KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Other Accumulated Expenses (2016 - 2026)

Palvella Therapeutics has reported Other Accumulated Expenses over the past 10 years, most recently at $483000.0 for Q4 2022.

  • Quarterly Other Accumulated Expenses rose 22.9% to $483000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $483000.0 through Dec 2022, up 22.9% year-over-year, with the annual reading at $483000.0 for FY2022, 22.9% up from the prior year.
  • Other Accumulated Expenses was $483000.0 for Q4 2022 at Palvella Therapeutics, down from $581000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $2.5 million in Q1 2018 and troughed at $173000.0 in Q2 2021.
  • The 5-year median for Other Accumulated Expenses is $595500.0 (2022), against an average of $761500.0.
  • Year-over-year, Other Accumulated Expenses plummeted 67.23% in 2020 and then surged 252.6% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $945000.0 in 2018, then tumbled by 51.53% to $458000.0 in 2019, then dropped by 24.24% to $347000.0 in 2020, then increased by 13.26% to $393000.0 in 2021, then rose by 22.9% to $483000.0 in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Other Accumulated Expenses are $483000.0 (Q4 2022), $581000.0 (Q3 2022), and $610000.0 (Q2 2022).